Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.26

Margin Of Safety %

Put/Call OI Ratio

0.49

EPS Next Q Diff

EPS Last/This Y

0.44

EPS This/Next Y

-0.15

Price

15.32

Target Price

25.04

Analyst Recom

1.32

Performance Q

-7.14

Relative Volume

0.64

Beta

0.5

Ticker: HCM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08HCM14.550.520.00444
2025-05-09HCM14.20.500.91451
2025-05-12HCM13.90.500.91451
2025-05-13HCM13.140.500.91451
2025-05-14HCM13.310.500.91451
2025-05-15HCM13.010.500.91451
2025-05-16HCM13.350.520.00471
2025-05-19HCM13.510.440.00257
2025-05-20HCM13.290.440.50257
2025-05-21HCM13.220.440.50257
2025-05-22HCM13.260.440.50257
2025-05-23HCM13.390.440.50257
2025-05-27HCM13.43N/AN/A0
2025-05-28HCM13.19N/AN/A0
2025-05-29HCM13.89N/AN/A0
2025-05-30HCM13.92N/AN/A0
2025-06-02HCM13.570.440.00272
2025-06-03HCM14.70.451.67268
2025-06-04HCM15.340.490.00283
2025-06-05HCM15.270.49999.99283
2025-06-06HCM15.320.49999.99283
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08HCM14.55- 161.50.17
2025-05-09HCM14.21- 166.80.17
2025-05-12HCM13.92- 167.20.17
2025-05-13HCM13.14- 155.00.17
2025-05-14HCM13.27- 162.70.17
2025-05-15HCM13.09- 166.20.17
2025-05-16HCM13.36- 171.80.17
2025-05-19HCM13.48- 171.00.17
2025-05-20HCM13.27- 167.20.17
2025-05-21HCM13.24- 168.60.17
2025-05-22HCM13.27- 169.10.17
2025-05-23HCM13.41- 164.20.17
2025-05-27HCM13.41- 174.40.17
2025-05-28HCM13.20- 166.90.17
2025-05-29HCM13.88- 195.50.17
2025-05-30HCM13.89- 185.60.17
2025-06-02HCM13.60- 178.20.17
2025-06-03HCM14.70- 187.40.17
2025-06-04HCM15.33- 184.90.17
2025-06-05HCM15.26- 175.60.64
2025-06-06HCM15.32- 176.30.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08HCM0.00-3.470.29
2025-05-09HCM0.00-3.470.29
2025-05-12HCM0.00-7.120.25
2025-05-13HCM0.00-7.120.25
2025-05-14HCM0.00-7.120.25
2025-05-15HCM0.00-7.120.25
2025-05-16HCM0.00-7.120.25
2025-05-19HCM0.00-7.280.25
2025-05-20HCM0.00-7.280.25
2025-05-21HCM0.00-7.280.25
2025-05-22HCM0.00-7.280.25
2025-05-23HCM0.00-7.280.25
2025-05-27HCM0.00-3.490.25
2025-05-28HCM0.00-3.490.26
2025-05-29HCM0.00-3.490.26
2025-05-30HCM0.00-3.490.26
2025-06-02HCM0.00-3.400.26
2025-06-03HCM0.00-3.400.26
2025-06-04HCM0.00-3.400.26
2025-06-05HCM0.00-3.400.26
2025-06-06HCM0.00-3.400.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-3.4

Beta

0.5

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

67

Growth Score

52

Sentiment Score

71

Actual DrawDown %

65.1

Max Drawdown 5-Year %

-82.2

Target Price

25.04

P/E

71.03

Forward P/E

26.95

PEG

1.17

P/S

4.25

P/B

3.52

P/Free Cash Flow

EPS

0.22

Average EPS Est. Cur. Y​

0.64

EPS Next Y. (Est.)

0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.99

Relative Volume

0.64

Return on Equity vs Sector %

-19.1

Return on Equity vs Industry %

-2.9

EPS 1 7Days Diff

0.5

EPS 1 30Days Diff

0.47

EBIT Estimation

176.3
HUTCHMED (China) Limited
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1811
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
stock quote shares HCM – HUTCHMED (China) Limited Stock Price stock today
news today HCM – HUTCHMED (China) Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch HCM – HUTCHMED (China) Limited yahoo finance google finance
stock history HCM – HUTCHMED (China) Limited invest stock market
stock prices HCM premarket after hours
ticker HCM fair value insiders trading